Gain Net Profit Margin from 2010 to 2024

GANX Stock  USD 1.67  0.09  5.11%   
Gain Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2024. Net Loss is the percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(403.54)
Current Value
(383.37)
Quarterly Volatility
117.66106456
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Gain Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gain Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 150 K, Net Interest Income of 579.3 K or Depreciation And Amortization of 44.3 K, as well as many indicators such as Price To Sales Ratio of 733, Dividend Yield of 0.0 or PTB Ratio of 3.55. Gain financial statements analysis is a perfect complement when working with Gain Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Gain Therapeutics Correlation against competitors.
For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

Latest Gain Therapeutics' Net Profit Margin Growth Pattern

Below is the plot of the Net Profit Margin of Gain Therapeutics over the last few years. It is the percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue. Gain Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gain Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Profit Margin10 Years Trend
Slightly volatile
   Net Profit Margin   
       Timeline  

Gain Net Profit Margin Regression Statistics

Arithmetic Mean(110.43)
Coefficient Of Variation(106.55)
Mean Deviation79.28
Median(53.64)
Standard Deviation117.66
Sample Variance13,844
Range350
R-Value(0.69)
Mean Square Error7,767
R-Squared0.48
Significance0
Slope(18.21)
Total Sum of Squares193,818

Gain Net Profit Margin History

2024 -383.37
2023 -403.54
2022 -125.55
2021 -84.19
2020 -123.88
2019 -53.11

About Gain Therapeutics Financial Statements

Gain Therapeutics investors use historical fundamental indicators, such as Gain Therapeutics' Net Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Gain Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss(403.54)(383.37)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.